269 related articles for article (PubMed ID: 30953666)
1. Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.
Gérard C; Di-Luoffo M; Gonay L; Caruso S; Couchy G; Loriot A; Castven D; Tao J; Konobrocka K; Cordi S; Monga SP; Hanert E; Marquardt JU; Zucman-Rossi J; Lemaigre FP
J Hepatol; 2019 Aug; 71(2):323-332. PubMed ID: 30953666
[TBL] [Abstract][Full Text] [Related]
2. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
3. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
4. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
7. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
[TBL] [Abstract][Full Text] [Related]
9. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
Li H; Yuan R; Wang H; Li C; Wei J
J BUON; 2020; 25(2):972-980. PubMed ID: 32521894
[TBL] [Abstract][Full Text] [Related]
11. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
12. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
13. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
Cadoux M; Caruso S; Pham S; Gougelet A; Pophillat C; Riou R; Loesch R; Colnot S; Nguyen CT; Calderaro J; Celton-Morizur S; Guerra N; Zucman-Rossi J; Desdouets C; Couty JP
J Hepatol; 2021 Jun; 74(6):1386-1397. PubMed ID: 33484773
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
[TBL] [Abstract][Full Text] [Related]
15. CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma.
Fan X; Ma X; Cui L; Dang S; Qu J; Zhang J; Wang X; Mao Z
Oncotarget; 2016 Dec; 7(49):80404-80414. PubMed ID: 27829235
[TBL] [Abstract][Full Text] [Related]
16. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
17. Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
Cheung PF; Cheung TT; Yip CW; Ng LW; Fung SW; Lo CM; Fan ST; Cheung ST
Oncotarget; 2016 Apr; 7(16):21644-57. PubMed ID: 26942873
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
19. Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling.
Qiao W; Wang H; Zhang X; Luo K
Gene; 2019 Jan; 681():7-14. PubMed ID: 30248355
[TBL] [Abstract][Full Text] [Related]
20. CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/β-catenin pathway.
Tan A; Li Q; Chen L
Arch Biochem Biophys; 2019 Jan; 661():196-202. PubMed ID: 30468709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
